Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.59 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.59 |
| ▸ | DGKA | P23743 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8344879 | 1.00 | PRKCA (0.59) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL27075588 | 1.00 | PRKCA (0.59) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL26664264 | 1.00 | PRKCA (0.59) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL27972239 | 1.00 | PRKCA (0.59) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8344666 | 1.00 | PRKCA (0.59) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| Ethylene Glycol SCHEMBL26618283 | 0.97 | PRKCA (0.56) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL9808018 | 0.96 | FAAH (0.62) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL3827843 | 0.95 | FAAH (0.64) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| Phosphoric Acid SCHEMBL28730747 | 0.95 | S1PR1 (0.56) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL27075587 | 0.95 | FAAH (0.64) | PRKCAPRKCEPRKCQPRKCDDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090328-A1 | WNT7a MRNA LIPID NANOPARTICLES FOR THERAPEUTIC USES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-04-30 | — | — | WO | claimed |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | MELBOURNE INST TECH (AU) | 2025-11-06 | — | — | US | claimed |
| US-20250319035-A1 | CATIONIC LIPID NANOPARTICLE HAVING HIGH TRANSFECTION EFFICIENCY AND PREPARATION METHOD THEREFOR | TONG, Shuwen (CN) | 2025-10-16 | — | — | US | claimed |
| EP-4584278-A1 | 2-AMINOPROPANE-1,3-DIOL-CAPPED CATIONIC PEPTOIDS FOR NUCLEIC ACID DELIVERY | Nutcracker Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | claimed |
| WO-2025137277-A1 | DEGRADABLE PEPTOIDS | NUTCRACKER THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4531812-A1 | LIPID NANOCARRIER VACCINE | Royal Melbourne Institute of Technology (AU) | 2025-04-09 | — | — | EP | claimed |
| CN-119630637-A | Ionizable cationic lipids and lipid nanoparticles and methods of synthesis and use thereof | 潮汐疗法公司 | 2025-03-14 | — | — | CN | claimed |
| US-20240307526-A1 | COMPOSITIONS COMPRISING HYDROXYETHYL-CAPPED CATIONIC PEPTOIDS | MEDICI THERAPEUTICS, INC. | 2024-09-19 | — | — | US | claimed |
| EP-4380949-A1 | COMPOSITIONS COMPRISING HYDROXYETHYL-CAPPED CATIONIC PEPTOIDS | Nutcracker Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | claimed |
| WO-2024054617-A1 | 2-AMINOPROPANE-1,3-DIOL-CAPPED CATIONIC PEPTOIDS FOR NUCLEIC ACID DELIVERY | NUTCRACKER THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | claimed |
| CN-112691078-A | Pharmaceutical composition for oral administration comprising taxane | 大化制药株式会社 | 2021-04-23 | — | — | CN | claimed |
| WO-2021046260-A1 | ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES | ARCTURUS THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | WO | claimed |
| CN-106999440-B | Pharmaceutical composition for oral administration comprising taxane | 大化制药株式会社 | 2021-02-12 | — | — | CN | claimed |
| EP-2188396-A2 | GENE SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS) | Vendevia Group, LLC (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2009035804-A2 | GENE SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS) | ONCOMUNE, LLC (US) | 2009-03-19 | — | — | WO | claimed |
| EP-0871758-B1 | LIPOSOMAL TRANSFECTION METHOD | KINNUNEN PAAVO KAI JOHANNES (FI) | 2004-03-31 | — | — | EP | claimed |
| US-6074667-A | Liposomal transfection method | KINNUNEN PAAVO (FI) | 2000-06-13 | — | — | US | claimed |
| EP-0871758-A1 | LIPOSOMAL TRANSFECTION METHOD | KINNUNEN, Paavo Kai Johannes (FI) | 1998-10-21 | — | — | EP | claimed |
| WO-1997019184-A1 | LIPOSOMAL TRANSFECTION METHOD | KINNUNEN PAAVO (FI) | 1997-05-29 | — | — | WO | claimed |
| US-5358714-A | Diacylglycerols as chemical activators of protein kinase C enzymes for inducing and increasing hair growth | UNILEVER PATENT HOLDINGS B.V. (NL) | 1994-10-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319035-A1 | CATIONIC LIPID NANOPARTICLE HAVING HIGH TRANSFECTION EFFICIENCY AND PREPARATION METHOD THEREFOR | CETP, NPC1L1, LIPA | PRKCA 517/4885PRKCE 1125/4885PRKCQ 565/4885 |
| US-20240307526-A1 | COMPOSITIONS COMPRISING HYDROXYETHYL-CAPPED CATIONIC PEPTOIDS | TLR9, TLR3, MICA | PRKCA 1610/4885PRKCE 1883/4885PRKCQ 1175/4885 |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | CD47, LY96, TSG101 | PRKCA 2423/4885PRKCE 2879/4885PRKCQ 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.